Home » Resources

Resources

Amphotericin B

Jina Pharmaceuticals Publication
Nanosomal Amphotericin B is an efficacious alternative to Ambisome® for fungal therapy. Int. J. Pharmaceutics, 397, (2010), 103-108.
Related Links


Tacrolimus

Jina Pharmaceuticals Publication
Polyoxyl 60 hydrogenated castor oil Free Nanosomal Formulation of Immunosuppressant Tacrolimus: Pharmacokinetics, Safety, and Tolerability in Rodents and Humans. Intl. Immunopharm, 10 (3), (2010), 325-330.
Related Links


Endoxifen

Jina Pharmaceuticals Publications

1. Endoxifen-a new cornerstone for breast cancer therapy: Demonstration of safety tolerability, and systemic bioavailability in healthy human  subjects. Clin. Pharm. & Ther., 88, (2010), 814-817.

2. Orally administered endoxifen is a new therapeutic agent for breast cancer. Breast Can. Res. Treat. 122, (2010), 579-584.

3. Endoxifen is a new Potent Inhibitor of PKC: A Potential Therapeutic Agent for Bipolar Disorder. Biorg. Med. Chem. Lett. 20, (2010), 2665-2667.

Presentations

1. First Clinical Study of Endoxifen Shows Favorable Safety and Pharmacokinetics in Humans: Paving the Path to Replace Tamoxifen. 39th American College of Clinical Pharmacology Annual Meeting, Baltimore, MD, September 12-14, 2010.

2. First Human Study Evaluating Safety and Pharmacokinetics of Endoxifen, A Potent Estrogen-Receptor Antagonist For Breast Cancer. 2010 ASCO Annual Meeting, Chicago, IL, June 4-8, 2010.

3. First-in-Human Study of Endoxifen: Oral Single Dose Of Endoxifen, A Potent Estrogen-Receptor Antagonist For Breast Cancer Is Safe, Tolerable    And Systemically Bioavailable In Healthy Human Subjects. 2010 American Society of Clinical pharmacology and therapeutics Annual Meeting Atlanta, Georgia, March 17-21, 2010.

Related Links